Figure 4.

Photos of a representative patient who had progressed on prior anti-PD-1 therapy but experienced a complete response after treatment with intratumoral V937 plus ipilimumab. This patient was resistant to pembrolizumab and had an area of isolated progression (day −28). He was subsequently started on combination therapy with intratumoral V937 plus ipilimumab. After an initial increase in lesion size (day 36), a durable response was achieved. On day 85, a new lesion developed while on therapy (see orange arrow). As injections were no longer needed at the other sites, the new lesion was injected starting on day 85 and then completely regressed. anti-PD-1, antiprogrammed death 1; D, day.